Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

totally blind individuals. Top line efficacy results are expected in mid 2012 and an NDA submission is planned for the first half of 2013.

On March 8, 2011, tasimelteon was granted orphan drug designation by the European Commission (EC) for the treatment of N24HSWD in totally blind individuals.  Orphan designation for a medicinal product by the EC provides benefits that can take a variety of forms including tax incentives, protocol assistance, eligibility for grants and initiatives supporting research and development related to this orphan indication, reduction of marketing application fees and annual fees for qualifying companies, and potential marketing exclusivity for up to 10 years in the European Union.

REVISED FULL YEAR 2011 FINANCIAL GUIDANCE

  • General and administrative expenses are expected to be between $10.0 and $12.0 million.  
  • Research and development expenses are expected to be between $30.0 and $34.0 million.  
  • Total U.S. GAAP operating expenses are expected to be between $41.0 and $47.0 million.  This includes $1.5 million related to amortization of an intangible asset and $5.0 to $6.0 million of stock-based compensation.

  • CONFERENCE CALLVanda has scheduled a conference call for today, Thursday, May 5, 2011, at 10:00 AM ET.  During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and James P. Kelly, Senior Vice President and Chief Financial Officer, will discuss the first quarter 2011 results and other corporate activities.  Investors can call 1-866-383-7998 (domestic) and 1-617-597-5329 (international) prior to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos (participant passcode 44118664).  A replay of the call will be available beginning Thursday, May 5, 2011 at 1:00 PM ET and will be accessible until Thursday, May 12, 2011, at 5:00 PM ET.  The replay call-in number is 1-888-286-
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
    2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
    3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
    4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
    6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
    7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
    8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
    9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
    (Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
    (Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
    (Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
    Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
    ... Woo Young Lee of the Chemical Engineering and ... of Chemistry, Chemical Biology and Biomedical Engineering at ... NSF funding for their research entitled, "Evaporative Assembly ... is a reflection of the pioneering work being ...
    ... 20 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or ... that its Special Meeting of Shareholders held today, its shareholders, ... excluding Mr. Han, voted to approve the merger of Datong ... to the Agreement and Plan of Merger dated March ...
    ... PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing ... entered into a purchase agreement to sell $3.9 million of ... registered public offering.   , , ... Under the terms of the purchase agreement, PharmAthene will sell an aggregate ...
    Cached Biology Technology:NSF funds infection-resistant orthopedic research 2Dragon Pharma shareholders approve merger and seek termination of listing on the OTCBB and TSX 2PharmAthene Announces $3.9 Million Registered Direct Offering 2PharmAthene Announces $3.9 Million Registered Direct Offering 3
    (Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
    (Date:4/17/2014)... about one per eight hundred births, Down syndrome - ... cause of intellectual disability. It results from a chromosomal ... copy of chromosome 21 (1% of the human genome). ... in the Department of Genetic Medicine and Development at ... in Nature , shed light on how the ...
    (Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
    Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
    ... African-American women who get breast cancer often get more aggressive ... women. But a Georgia State University researcher has found ... which would let their doctors customize their treatment. Ritu ... called HSET. Earlier studies have linked elevated levels of HSET ...
    ... 2013  DigitalPersona, Inc., a trusted partner for biometric ... ® FingerJet ® Recognition Engine matching ... of Standards and Technology (NIST) and the MINEX ... States Government,s  Personal Identity Verification (PIV) standards.  ...
    ... Dec. 10, 2013 Kurt H. Becker , the ... at the Polytechnic Institute of New York University (NYU-Poly), has ... Inventors (NAI).  Becker was chosen by ... facilitating outstanding inventions that have made a tangible impact on ...
    Cached Biology News:DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2Kurt H. Becker Named a Fellow of the National Academy of Inventors 2Kurt H. Becker Named a Fellow of the National Academy of Inventors 3
    ... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
    BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
    ... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains, Aga1 and Aga2, to display recombinant ...
    Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
    Biology Products: